期刊
VACCINE
卷 28, 期 27, 页码 4423-4429出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.04.036
关键词
Plasmodium falciparum; Transmission-blocking vaccine; Vaccine development
资金
- National Institute of Allergy and Infectious Diseases/NIH
Plasmodium falciparum surface protein 25 (Pfs25) is a candidate for transmission-blocking vaccines (TBVs). Anti-Pfs25 antibodies block the development of oocysts in membrane-feeding assays and we have shown the activity correlates with antibody titer. In this study, we purified Pfs25-specific IgGs to convert antibody titer to p,mu g/mL and determined the amount of antibody required to inhibit 50% of oocyst development (IC50). The IC50 were, 15.9, 4.2, 41.2, and 85.6 mu g/mL for mouse, rabbit, monkey and human, respectively, and the differences among species were significant. Anti-Pfs25 sera from rabbit, monkey and human showed different patterns of competition against 6 mouse monoclonal antibodies, and the avidity of antibodies among four species were also different. These data suggests that information obtained from animal studies which assess efficacy of TBV candidates may be difficult to translate to human immunization. (C) 2010 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据